1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

 
• By Deanna Kamienski

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

Biopharmaceutical start-ups brought in 19% less funding in the first quarter of 2017 as compared with the previous quarter, but venture capital investors placed big bets on a few new companies, including a $150m Series A round for Vir Biotechnology Inc. helmed by Biogen's former CEO.

But while venture capital financings declined from one quarter to another, big pharmas and others continued to tap into the innovation occurring at start-up firms. AbbVie Inc., Takeda Pharmaceutical Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.